Novel Strategies to Improve the Endocrine Therapy of Breast Cancer.

Oncol Rev · 2017 · PMC5444409 · PMID 28584571

Europe PMC DOI

hedged sentence

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

did not reach statistical significanceP=0.14not close (p > 0.1)

Although PFS in this study was increased to 18.4 months with the addition of bevacizumab vs 13.4 without, it did not reach statistical significance (P=0.14).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.